Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer

Abstract

No AccessJournal of UrologyChemotherapy1 Mar 1992Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer Andrew D. Seidman, Howard I. Scher, Daniel Petrylak, D. David Dershaw, and Tracy Curley Andrew D. SeidmanAndrew D. Seidman , Howard I. ScherHoward I. Scher , Daniel PetrylakDaniel Petrylak , D. David DershawD. David Dershaw , and Tracy CurleyTracy Curley View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)37426-8AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The combination of estramustine phosphate and vinblastine sulfate, 2 agents with separate and unique antimicrotubular effects, has demonstrated additive cytotoxicity against the DU145 human prostate derived cell line in vitro. We evaluated this combination in 25 patients with progressive hormone refractory prostate cancer. Of 24 patients with an elevated prostate specific antigen (PSA) level at the start of treatment 13 (54%, 95% confidence limits 34 to 74%) had a greater than 50% decrease in PSA levels on at least 3 consecutive biweekly determinations. The median decrease in PSA in responding patients was 64% (mean 71.7%) and the median duration of response was 7 months. In 5 patients with bidimensionally measurable disease 2 partial responses were observed. Treatment was well tolerated, with mild and manageable toxicity. This is a well tolerated outpatient treatment regimen for patients with hormone-refractory prostatic cancer which deserves further investigation. © 1992 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByScher H and Kelly W (2018) Editorial: States and State Transitions are All That Really MatterJournal of Urology, VOL. 168, NO. 6, (2451-2453), Online publication date: 1-Dec-2002.OH W and KANTOFF P (2018) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTSJournal of Urology, VOL. 160, NO. 4, (1220-1229), Online publication date: 1-Oct-1998.Joyce R, Fenton M, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin M and Bubley G (2018) HIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPYJournal of Urology, VOL. 159, NO. 1, (149-153), Online publication date: 1-Jan-1998.Hartley-Asap B, Vukanovic J, Joseph I, Strandgarden K, Polacek J and Isaacs J (2018) Anti-Angiogenic Treatment with Linomide as Adjuvant to Surgical Castration in Experimental Prostate CancerJournal of Urology, VOL. 158, NO. 3, (902-907), Online publication date: 1-Sep-1997.Iversen P, Rasmussen F, Asmussen C, Christensen I, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S and Rosenkilde P (2018) Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002Journal of Urology, VOL. 157, NO. 3, (929-934), Online publication date: 1-Mar-1997.Cox R and Crawford E (2018) Estrogens in the Treatment of Prostate CancerJournal of Urology, VOL. 154, NO. 6, (1991-1998), Online publication date: 1-Dec-1995. Volume 147Issue 3 Part 2March 1992Page: 931-934 Advertisement Copyright & Permissions© 1992 by The American Urological Association Education and Research, Inc.Keywordsdifferentiationprostatic neoplasmsantigensnitrogen mustard compoundsvinblastineMetricsAuthor Information Andrew D. Seidman More articles by this author Howard I. Scher More articles by this author Daniel Petrylak More articles by this author D. David Dershaw More articles by this author Tracy Curley More articles by this author Expand All Advertisement Loading ...